Capital Fund Management S.A. Makes New $2.11 Million Investment in Genmab A/S Sponsored ADR $GMAB

Key Points

• Capital Fund Management S.A. acquired 107,523 shares of Genmab A/S, valued at approximately $2,105,000, highlighting the institutional investment interest in the company.
• Several analysts have rated Genmab A/S positively, with Truist Financial boosting their price objective to $46.00 and maintaining a "buy" rating, while Zacks Research downgraded it to a "hold."
• Genmab A/S reported an earnings per share (EPS) of $0.54, exceeding analysts' expectations, but its revenue of $925 million fell short of the $5.77 billion forecast.

Capital Fund Management S.A. bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 107,523 shares of the company's stock, valued at approximately $2,105,000.

Other institutional investors have also recently made changes to their positions in the company. Deep Track Capital LP bought a new stake in Genmab A/S in the 4th quarter worth $41,740,000. Brandywine Global Investment Management LLC raised its holdings in Genmab A/S by 6.0% in the first quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock worth $33,627,000 after buying an additional 97,633 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Two Sigma Advisers LP grew its position in Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after buying an additional 1,038,400 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in shares of Genmab A/S by 102.4% in the fourth quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company's stock worth $23,170,000 after purchasing an additional 561,767 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.26 on Friday, reaching $24.86. The company had a trading volume of 442,003 shares, compared to its average volume of 1,434,567. The firm has a market capitalization of $15.95 billion, a PE ratio of 12.48, a P/E/G ratio of 7.19 and a beta of 0.95. The firm has a 50-day moving average of $22.15 and a 200-day moving average of $21.23. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $27.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Zacks Research downgraded shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Finally, Truist Financial upped their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.60.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.